Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function

Clinical and Experimental Nephrology

Volumn 15, Issue 5, 2011, Pages 700-707

  Moriyama, Takahito ^a   Amamiya, Nobuyuki ^a   Ochi, Ayami ^a   Tsuruta, Yuki ^a   Shimizu, Ari ^a   Kojima, Chiari ^a   Itabashi, Mitsuyo ^a   Takei, Takashi ^a   Uchida, Keiko ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; IgA nephropathy; Urinary protein excretion

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; RISK FACTOR; SURVIVAL RATE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY; BLOOD PRESSURE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 80755190024     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0455-8     Document Type: Article

References (26)

1. J Berger N Hinglais 1968 Les dépôts intercapillaries d'IgA-IgG J Urol Nephrol 74 694 695 1:STN:280:DyaF1M7lsVCjsA%3D%3D
2. J Barratt J Feehally 2006 Treatment of IgA nephropathy Kidney Int 69 1934 1938 16641928 10.1038/sj.ki.5000419 1:CAS:528:DC%2BD28XkvVyrsbg%3D (Pubitemid 43924255)
3. F Locatelli L Del Vecchio C Pozzi 2006 IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors Nat Clin Pract Nephrol 2 24 31 16932386 10.1038/ncpneph0055 1:CAS:528:DC%2BD28XhvVSrsr0%3D (Pubitemid 43355242)
4. FW Ballardie 2007 Quantitative appraisal of treatment options for IgA nephropathy J Am Soc Nephrol 18 2806 2809 17942959 10.1681/ASN.2007020182 1:CAS:528:DC%2BD2sXhtlGgsbrN (Pubitemid 350058385)
5. T Komatsu S Fujimoto S Hara A Fukuda K Fukudome K Yamada, et al. 2009 Recent therapeutic strategies improve renal outcome in patients with IgA nephropathy Am J Nephrol 30 19 25 19169006 10.1159/000197116 1:CAS:528:DC%2BD1MXot12ks7c%3D
6. K Asaba A Yojo ML Onozato S Kinugasa H Miyazaki K Miyashita, et al. 2009 Long-term renal prognosis of IgA nephropathy with therapeutic trend shifts Intern Med 48 83 90 10.2169/internalmedicine.48.1938
7. J Cheng W Zhang XH Zhang Q He XJ Tao JH Chen 2009 ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trial Int J Clin Pract 63 80 88 10.1111/j.1742-1241.2009.02038.x
8. JJ Dillon 2004 Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy Semin Nephrol 24 218 224 15156527 10.1016/j.semnephrol.2004.01.003 1:CAS:528:DC%2BD2cXlsFCgsr4%3D (Pubitemid 38685991)
9. K Joh 2008 Proposal for a new histological classification of IgA nephropathy in Japan and a preliminary report of the international clinic-pathological classification of IgA nephropathy Jpn J Nephrol 50 448 455
10. M Praga E Gutiérrez E González E Morales E Hernández 2003 Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial J Am Soc Nephrol 14 1578 1583 12761258 10.1097/01.ASN. 0000068460.37369.DC 1:CAS:528:DC%2BD3sXjslanur0%3D (Pubitemid 36687059)
11. Y Kanno H Okada Y Yamaji Y Nakazato H Suzuki 2005 Angiotensin-converting- enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation QJM 98 199 203 15728401 10.1093/qjmed/hci036 1:STN:280:DC%2BD2M%2FpvFajsQ%3D%3D (Pubitemid 40361317)
12. T Nakamura C Ushiyama S Suzuki M Hara N Shimada K Sekizuka, et al. 2000 Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy Am J Nephrol 20 373 379 11092994 10.1159/000013619 1:STN:280:DC%2BD3M%2FmtlCmsQ%3D%3D
13. PKT Li CB Leung KM Chow YL Cheng SKS Fung SK Mak, et al. 2006 Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study Am J Kidney Dis 47 751 760 16632013 10.1053/j.ajkd.2006.01.017 1:CAS:528:DC%2BD28XlsVCgsL0%3D
14. KT Woo CM Chan HK Tan HL Choong M Foo A Vathsala, et al. 2009 Beneficial effects of high-dose losartan in IgA nephritis Clin Nephrol 71 617 624 19473629 1:CAS:528:DC%2BD1MXovFSkt7o%3D
15. A Shimizu T Takei K Uchida K Tsuchiya K Nitta 2008 Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy Hypertens Res 31 1711 1717 18971549 10.1291/hypres.31.1711 1:CAS:528:DC%2BC3cXisVGhsLw%3D
16. Y Tomino T Kawamura K Kimura M Endoh T Hosoya S Horikoshi, et al. 2009 Antiproteinuric effect of olmesartan in patients with IgA nephropathy J Nephrol 22 224 231 19384840 1:CAS:528:DC%2BD1MXhs1WitbbO
17. KT Woo YK Lau KS Wong GSC Chiang 2000 ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis Kidney Int 58 2485 2491 11115082 10.1046/j.1523-1755.2000.00432.x 1:CAS:528: DC%2BD3MXitFSguw%3D%3D
18. D Russo R Minutolo A Pisani R Esposito G Signoriello M Andreucci, et al. 2001 Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy Am J Kidney Dis 38 18 25 11431176 10.1053/ajkd.2001. 25176 1:CAS:528:DC%2BD3MXlsFKnsrg%3D (Pubitemid 32611753)
19. Y Horita M Tadokoro K Taura N Suyama T Taguchi M Miyazaki, et al. 2004 Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy Hypertens Res 27 963 970 15894837 10.1291/hypres.27.963 1:CAS:528:DC%2BD2MXjvVGhtLc%3D (Pubitemid 40425399)
20. Y Horita K Taura T Taguchi A Furusu S Kohno 2006 Aldosterone breakthrough during therapy with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy Nephrology 11 462 466 17014562 10.1111/j.1440-1797.2006.00665.x 1:CAS:528:DC%2BD28Xht1enur%2FJ (Pubitemid 44470097)
21. N Miura H Imai S Kikuchi S Hayashi Kawamura T Endoh, et al. 2009 Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy Clin Exp Nephrol 13 460 466 19449181 10.1007/s10157-009-0179-1 1:CAS:528:DC%2BD1MXhsVertrnI
22. O Hotta M Miyazaki T Furuta S Tomioka S Chiba I Horigome, et al. 2001 Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy Am J Kidney Dis 38 736 743 11576876 10.1053/ajkd.2001.27690 1:STN:280:DC%2BD3MrivF2nsQ%3D%3D (Pubitemid 33666518)
23. O Hotta 2004 Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy Semin Nephrol 3 244 255 10.1016/j.semnephrol.2004.01.005 (Pubitemid 38685993)
24. GB Appel M Waldman 2006 The IgA nephropathy treatment dilemma Kidney Int 69 1939 1944 16641925 10.1038/sj.ki.5000434 1:CAS:528:DC%2BD28XkvVyrsbk%3D (Pubitemid 43924256)
25. DC Cattran C Greenwood S Ritchie 1994 Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients to receiving treatment with other antihypertensive agents and to patients receiving no therapy Am J Kidney Dis 23 247 254 8311083 1:STN:280:DyaK2c7ksVKntg%3D%3D (Pubitemid 24075319)
26. KT Woo YK Lau CM Chan KS Wong 2008 Angiotensin-converting enzyme inhibitor versus angiotensin 2 receptor antagonist therapy and the influence of angiotensin-converting enzyme gene polymorphism in IgA nephritis Ann Acad Med 37 372 376